Lite Strategy (LITS) Current Leases (2020 - 2024)
Lite Strategy (LITS) posted quarterly Current Leases of $1.1 million for Q1 2024, down 24.04% year-over-year from $1.4 million in Q2 2023, and up 3.65% quarter-over-quarter from $1.0 million in Q4 2023.
Lite Strategy (LITS) Current Leases (2020 - 2024) Analysis & Trends
Lite Strategy's Current Leases history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2024.
- In Q1 2024, Current Leases fell 24.04% year-over-year to $1.1 million; the TTM figure through Mar 2024 stood at $1.1 million (down 24.04% YoY), while the FY2023 annual figure was $1.4 million, up 63.95% from the prior year.
- Current Leases for Q1 2024 stood at $1.1 million, up from $1.0 million in the prior quarter.
- The five-year high for Current Leases was $1.4 million in Q2 2023, with the low at $602000.0 in Q3 2020.
- The 5-year median for Current Leases is $987000.0 (2021), against an average of $1.0 million.
- Peak annual rise in Current Leases reached 67.27% in 2023, while the deepest fall reached 24.42% in 2023.
- Lite Strategy's Current Leases stood at $873000.0 in 2020, then climbed by 13.06% to $987000.0 in 2021, then soared by 36.07% to $1.3 million in 2022, then declined by 24.42% to $1.0 million in 2023, then rose by 3.65% to $1.1 million in 2024.
- Business Quant data shows LITS's Current Leases at $1.1 million in Q1 2024, $1.0 million in Q4 2023, and $1.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.43 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 1.30 Mn |
| Jun 30, 2022 | 871,000.00 |
| Mar 31, 2022 | 828,000.00 |
| Dec 31, 2021 | 987,000.00 |
| Sep 30, 2021 | 957,000.00 |
| Jun 30, 2021 | 928,000.00 |
| Mar 31, 2021 | 900,000.00 |
| Dec 31, 2020 | 873,000.00 |
| Sep 30, 2020 | 602,000.00 |